Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

ABSTRACT: H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. From a wider screen of an epigenetic inhibitor library, we identified PRMT5 inhibitors as amongst the top hits reducing DMG cell viability. Here, we treated HSJD-DIPG-007 +/- the PRMT5 inhibitor LLY-283. RNA-sequencing was performed at 0, 1, 2, 3, 5, 7 and 10 days to assess the changes in gene expression following PRMT5 inhibition in DMG cells. This shows that PRMT5 inhibition changes expression in genes associated with multiple disease relevant phenotypes, including sterol metabolism, differentiation, and the extracellular matrix. By characterising the changes in the transcriptome following PRMT5 inhibition this provides crucial insights into the potential of PRMT5 inhibitors as a treatment for H3K27-altered DMG.

ORGANISM(S): Homo sapiens

PROVIDER: GSE230065 | GEO | 2024/01/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

Project description:PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

| PRJNA957302 | ENA

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line

Project description:Identification of super enhancer regions in the HSJD-DIPG-007 cell line and the associated genes with these regions. This study aims to evaluate the efficacy of combined use of BET and CBP inhibition in DIPG.

2020-08-01 | E-MTAB-8242 | biostudies-arrayexpress

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line upon treatment with ICG-001 and JQ1

2020-08-01 | E-MTAB-9152 | biostudies-arrayexpress

Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation

Project description:Characterisation of a new subgroup of DMG lacking H3-K27M mutation that is defined by H3K27me3 loss and EZHIP overexpression that can be detected by IHC. These tumors are distinct from EZHIP-positive posterior fossa ependymomas and are associated with a dismal prognosis. We propose that these EZHIP/H3-WT tumors need to be considered similar to canonical DIPG/DMG, thus extending the spectrum of DMG with PRC2 inhibition beyond H3-K27M mutation

2020-03-20 | E-MTAB-8888 | biostudies-arrayexpress

PRMT5 regulates the homologous recombination DNA repair pathway by controlling the alternative splicing of key epigenetic factors

Project description:We found that PRMT5 deletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA damage accumulation, p53 activation, cell cycle arrest and cell death through missplicing of KAT5. We show that PRMT5 inhibitors and PARP inhibitors have synergistic effects on human acute leukemia cell lines, demonstrating the advantages of combining targeted epigenetic and non-epigenetic inhibitors.

2018-09-04 | GSE107854 | GEO

Chip array data for Suit2-007 cells treated by riproximin (Rpx)

Project description:We report the effect of Rpx on human PDAC Suit2-007 cells after 48h time point

2020-09-01 | GSE152304 | GEO

RNA-sequencing (RNA-seq) in BxPC-3 and S2-007 cell lines

Project description:RNA sequencing technology has been carried out in order to compare mRNA expression changes in epithelial BxPC-3 versus mesenchymal S2-007 cells.

2018-04-18 | GSE113259 | GEO

The nitrone compound OKN-007 delays motor neuron loss and disease progression in the G93A mouse model of Amyotrophic Lateral Sclerosis

Project description:Our study investigated the therapeutic potential of OKN-007 in the SOD1 G93A mouse model of amyotrophic lateral sclerosis (ALS). The impact of OKN-007, known for its antioxidant, anti-inflammatory, and neuroprotective properties, was tested at two doses (150 mg/kg and 300 mg/kg) at onset and late-stage disease. Results demonstrated a significant delay in disease progression at both doses, with treated mice showing a slower advance to severe disease stages compared to untreated controls. Transcriptomic analysis using bulk RNA sequencing identified dysregulated genes in G93A mice that were restored by OKN-007 treatment and pathways that showed altered expression in response to OKN-007. Overall, our findings suggest that OKN-007 holds potential as a disease-modifying treatment for ALS, although further research is needed to optimize dosing regimens and understand its long-term effects.

2024-11-10 | GSE281064 | GEO

Rhizobium sp. 007

Project description:Rhizobium sp. 007 Genome sequencing

| PRJNA674303 | ENA

The histogenetic origin of malignant cells predicts their cyto-toxicity towards synthetic lethality utilizing the TK.007 system

Project description:The efficacy of killing human cancer cells by a modified Herpes-simplex-virus thymidine kinase TK.007/ganciclovir (GCV) system was investigated in malignant cells of different histogenetic origin. The aim was to determine whether different histogenetic origins of cancer cells in them-selves influence their reaction towards an approach of synthetic lethality, which theoretically should be applicable independently of the cell type. Fifteen malignant human cell lines were transduced with a lentiviral vector to stably express the TK.007 gene and cell proliferation assays under GCV were performed. Among TK.007-expressing cell lines, lymphoma and leuke-mia cells were more susceptible to killing than solid cancer cells, while osteosarcoma and mela-noma cells exhibited an intermediate susceptibility. Similar differences in killing were also noted in wild-type non-transduced cells. This study highlights that the histogenetic origin of malignant cells strongly influences their susceptibility towards cytotoxic agents, with leukemias and lym-phomas being more sensitive than solid cancer cells.

2025-01-17 | PXD052713 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data